Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 17, 2016 - Issue 2
Submit an article Journal homepage
882
Views
15
CrossRef citations to date
0
Altmetric
Reviews

Pharmacological treatment of schizophrenia with comorbid substance use disorder

Jean-Michel AzorinDepartment of Psychiatry and Addiction Medicine, South Hospitals, Marseille, FranceCorrespondence[email protected]
,
Nicolas SimonAix-Marseille University, INSERM, UMR912 (SESSTIM), Marseille, France
,
Marc AdidaDepartment of Psychiatry and Addiction Medicine, South Hospitals, Marseille, France
&
Raoul BelzeauxDepartment of Psychiatry and Addiction Medicine, South Hospitals, Marseille, France
Pages 231-253 | Received 15 Jun 2015, Accepted 26 Oct 2015, Published online: 04 Dec 2015

References

  • Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers
  • Frischer M, Collins J, Millson D, et al. Prevalence of comorbid psychiatric illness and substance misuse in primary care in England and Wales. J Epidemiol Community Health. 2004;58:1036–1041.
  • Moore E, Mancuso SG, Slade T, et al. The impact of alcohol and illicit drugs on people with psychosis: the second Australian National Survey of Psychosis. Aust N Z Psychiatry. 2012;46:864–878.
  • Kavanagh DJ, McGrath J, Saunders JB, et al. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs. 2002;62:743–755.
  • Gupta S, Hendricks S, Kenkel AM, et al. Relapse in schizophrenia: is there a relationship to substance abuse?. Schizophr Res. 1996;20:-153-156.
  • Green AI, Salomon MS, Brenner MJ, et al. Treatment of schizophrenia and comorbid substance use disorder. Curr Drug Targets CNS Neurol Disord. 2002;1:129–139.
  • Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA. 1990;264:2511–2518.
  • George TP, Vessichio JC, Termine A. Nicotine and tobacco use in schizophrenia. In: Meyer JM, Nasrallah HA, editors. Medical illness and schizophrenia. Arlington: American Psychiatric Publishing. Inc; 2003. p. 81–98.
  • Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry. 2001;50:71–83.
  • Littrel KH, Petty RG, Hilligoss NM, et al. Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat. 2001;21:217–221.
  • Soyka M, Albus M, Kathmann N, et al. Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci. 1993;242:362–372.
  • Cohen LJ, Test MA, Brown RL. Suicide and schizophrenia: data from a prospective community treatment study. Am J Psychiatry. 1990;147:602–607.
  • Haywood TW, Kravitz HM, Grossman LS, et al. Predicting the “revolving door” phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry. 1995;152:856–861.
  • Kovasznay B, Fleischer J, Tanenberg-Karant M, et al. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull. 1997;23:195–201.
  • Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51:273–279.
  • Rasanen P, Tiihonen J, Isohanni M, et al. Schizophrenia, alcohol abuse, and violent behavior: a 23-year followup study of an unselected birth cohort. Schizophr Bull. 1998;24:437–441.
  • Seibyl JP, Satel SL, Anthony D, et al. Effects of cocaine on hospital course in schizophrenia. J Nerv Ment Dis. 1993;181:31–37.
  • Swofford CD, Kasckow JW, Scheller-Gilkey G, et al. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res. 1996;20:145–151.
  • Swartz MS, Wagner HR, Swanson JW, et al. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis. 2006;194:164–172.
  • Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry. 1985;142:1259–1264.

•• A presentation of the most classic hypothesis about the comorbidity of schizophrenia and SUD.

  • Blanchard JJ, Squires D, Henry T, et al. Examining an affect regulation model of substance abuse in schizophrenia: the role of traits and coping. J Nerv Ment Dis. 1999;187:72–79.
  • Green AI, Zimmets SV, Strous RD, et al. Clozapine for comorbid substance use disorder and schizophrenia: do patients have a reward-deficiency syndrome that can be ameliorated by clozapine?. Harv Rev Psychiatry. 1999;6:287–296.
  • Samaha AN. Can antipsychotic treatment contribute to drug addiction in schizophrenia?. Progress Neur Psychopharmacol Biol Psychiatry. 2014;52:9–16.

•• An excellent review on the reasons why drug abuse and addiction are so prevalent in schizophrenia and which makes the case for a contribution of FGAs to drug addiction.

•• An excellent review on the pharmacological treatment of schizophrenic patients with SUD, which stays very close to the preoccupations of clinicians.

•• A comprehensive review in the field which details for each antipsychotic the available evidence.

  • Smelson DA, Dixon L, Craig T, et al. Pharmacological treatment of schizophrenia and co-occuring substance use disorders. CNS Drugs. 2008;22:903–916.

•• An outstanding review with a clear presentation of the different studies comparing FGAs vs SGAs as well as SGAs between them, and those about US-FDA-approved medications specifically for the treatment of SUD.

  • Wobrock T, Soyka M. Pharmacotherapy of schizophrenia with comorbid substance use disorder. Reviewing the clinical evidence and recommendations. Progr Neuropharmacol Biol Psychiatry. 2008;32:1375–1385.

•• An excellent review on psychotropic drugs and anticraving agents for the treatment of schizophrenia comorbid with SUD, accompanied by treatment recommendations.

•• An excellent review of open studies and RCTs conducted in schizophrenic patients with SUD which provides expert opinion on this topic.

  • Zhornitsky S, Rizkallah E, Pampoulova T, et al. Antipsychotic agents for the treatment of substance use disorders in patients with comorbid psychosis. J Clin Psychopharmacol. 2010;30:417–424.

•• An informative review on clinical studies of antipsychotics for substance users with and without comorbid psychosis.

  • Sepede G, Lorusso M, Spano MC, et al. Substance use in schizophrenia: efficacy of atypical antipsychotics. J Schizophr Res. 2014;1:1–12.

•• An evidence-based review focusing on the clinical studies of antipsychotics for the treatment of schizophrenic patients with SUD.

•• An interesting review on interventions for psychiatric patients with SUD not focused on schizophrenia, but also dealing with depression, bipolar disorders, and anxiety.

  • Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(b2535).
  • Green AI, Tohen MF, Hamer RM, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004;66:125–135.
  • Sayers SL, Campbell EC, Kondrich J, et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis. 2005;193:379–386.
  • Smelson DA, Ziedonis D, Williams J, et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol. 2006;26:9–12.
  • Rubio G, Martínez I, Ponce G, et al. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry. 2006;51:531–539.

•• The first RCT involving LAI antipsychotics in the treatment of schizophrenic patients with SUD.

  • Swartz MS, Wagner HR, Sawnson JW, et al. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr Res. 2008;100:39–52.
  • Akerele E, Levin FR. Comparison of olanzapine to risperidone in substance abusing individuals with schizophrenia. Am J Addic. 2007;16:260–268.
  • Van Nimwegen LJ, De Haan L, Van Beveren NJ, et al. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double blind randomized controlled trial. Can J Psychiatry. 2008;53:400–405.
  • Sevy S, Robinson DG, Sunday S, et al. Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. Psychiatry Res. 2011;188:310–314.
  • Schnell T, Koethe D, Krasnianski A, et al. Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. Am Addict. 2014;23:308–312.
  • McEvoy JP, Freudenreich O, McGee M, et al. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry. 1995;37:550–552.
  • McEvoy JP, Freudenreich O, Wilson WH. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry. 1999;46:125–129.
  • De Leon J, Diaz FJ, Josiassen RC, et al. Does clozapine decrease smoking?. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:757–762.
  • Brown ES, Nejtek VA, Perantec DC, et al. Cocaine and amphetamine use in patients with psychiatric illness. A randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol. 2003;23:284–288.
  • Brunette MF, Dawson R, O’Keefe CD, et al. A randomized trial of clozapine versus other antipsychotic for cannabis use disorder in patients with schizophrenia. J Dual Diagnosis. 2011;7:50–63.
  • Leatherman SM, Liang MH, Krystal JH, et al. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. J Nerv Ment Dis. 2014;202:13–17.
  • Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364:842–851.
  • Gawin FH, Khalsa-Denison ME, Jatlow P. Flupenthixol and desipramine treatment of crack users: double blind results. Eur Neuropsychopharmacol. 1996;6:120–121.
  • Kishi T, Matsuda Y, Iwata N, et al. Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2013;74:e1169–e1180.

•• An evidence-based demonstration of the overall lack of efficacy of antipsychotics for primary cocaine or psychostimulant dependence.

  • Shaw GK, Majumdar SK, Waller S, et al. Tiapride in the long term management of alcoholics of anxious or depressive temperament. Br J Psychiatry. 1987;150:164–168.
  • Shaw GK, Waller S, Sk M, et al Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry. 1994;165:515–523.
  • Gual A, Monras M. Eficacia de tiapride en el mantenimiento de la abstinencia en alcohólicos desintoxicados. Resultados de un ensayo clínicos a doble ciego frente a placebo. Adicciones. 2002;14:321–326.
  • Bender S, Scherbaum N, Soyka M, et al. The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence: a randomized double-blind placebo-controlled trial in 299 alcohol –dependent patients. Int J Neuropsychopharmacol. 2007;10:653–660.
  • Marra D, Warot D, Berlin I, et al. Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial. Alcohol Clin Exp Res. 2002;26:1545–1552.
  • Wiesbeck GA, Weijers HG, Lesch OM, et al. Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo controlled study. Alcohol Alcohol. 2001;36:329–334.
  • Hutchison KE, Ray L, Sandman E, et at. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology. 2006;31:1310–1317.
  • Guardia J, Segura L, Gonzalvo B, et al. A double-blind, placebo controlled study of olanzapine in the treatment of alcohol-dependence disorder. Alcohol Clin Exp Res. 2004;28:736–745.
  • Kampman KM, Pettinati HM, Lynch KG, et al. A double blind, placebo-controlled pilot trial of quetiapine for the treatment of type A and type B alcoholism. J Clin Psychopharmacol. 2007;27:344–351.
  • Litten RZ, Fertig JE, Falk DE, et al. A double blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012;36:406–416.
  • Anton RF, Kranzler H, Breder C, et al. A randomized, multicenter, double-blind placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008;28:5–12.
  • Martinotti G, Di Nicola M, Di Giannantonio M, et al. Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone. J Psychopharmacol. 2009;23:123–129.
  • Rounsaville BJ. DSM-V research agenda: substance abuse/ psychosis comorbidity. Schizophr Bull. 2007;33:947–952.
  • Jablensky A. Schizophrenia in DSM-5: assets and liabilities. Schizophr Res. 2013;150:36–37.
  • Berk M, Brook S, Trandafir AI. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized trial. Int Clin Psychopharmacol. 1999;14:177–180.
  • Berk M, Brook S, Nur F. Risperidone compared to haloperidol in cannabis-induced psychotic disorder: a double blind randomized controlled trial. Int J Psychiat Clin Pract. 2004;4:139–142.
  • Siris SG, Mason SE, Bermanzohn PC, et al. Adjunctive imipramine in substance-abusing dysphoric schizophrenia patients. Psychopharmacol Bull. 1993;29:127–133.
  • Wilkins JN, Gorelick DA, Levine D, et al. Double-blind trial of desipramine for treatment of cocaine-abusing schizophrenics. In: Harris LS editor. Problems of drug dependence, 1995. Proceedings of the 57th Annual Scientific Meeting. Rockville, MD: NS. Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse; 1996; 325.
  • Ziedonis D, Richardson T, Lee E, et al. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacol Bull. 1992;28:309–314.
  • Kleber HD, Weiss RD, Anton RF, et al. Treatment of patients with substance use disorders, second edition. American Psychiatry Association. Am J Psychiatry. 2007;164(4Suppl.):5–123.

•• An outstanding and extremely detailed review of evidence-based studies in the field, which provides clinicians with useful guidelines.

  • Brensilver M, Heinzerling KG, Shoptaw S. Pharmacotherapy of amphetamine-type stimulant dependence. Drug and Alcohol Review. 2013;32:449–469.
  • Fawcett J, Clark DC, Aagesen CA, et al. A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. Arch Gen Psychiatry. 1987;44:248–256.
  • Gawin FH, Kleber HD, Byck R, et al. Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry. 1989;46:117–181.
  • Petrakis IL, O’Malley S, Rounsaville B, et al. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl). 2004;172:291–297. Erratum in: Psychopharmacology (Berl). 2004;174:300.
  • Petrakis IL, Nich C, Ralevski E. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull. 2006;32:644–654.
  • Petrakis IL, Poling J, Levinson C, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry. 2005;57:1128–1137.
  • Ralevski E, O’Brien E, Jane S, et al. Treatment with acamprosate in patients with schizophrenia spectrum disorders and comorbid alcohol dependence. J Dual Diagnosis. 2011;7:64–73.
  • Chou KR, Chen R, Lee JF, et al. The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Int J Nurs Stud. 2004;41:321–330.
  • Chen HK, Lan TH, Wu BJ. A double-blind randomized clinical trial of different doses of transdermal nicotine patch for smoking reduction and cessation in long-term hospitalized schizophrenic patients. Eur Arch Psychiatry Clin Neurosci. 2013;263:75–82.
  • Allen MH, Debanné M, Lazignac C, et al. Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2011;168:395–399.
  • Weiner E, Buchholz A, Coffay A, et al. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res. 2011;129:94–95.
  • Williams JM, Anthenelli RM, Morris CD, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012;73:654–660.
  • Fatemi SH, Yousefi MK, Kneeland RE, et al. Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study. Schizophr Res. 2013;146:376–378.
  • Meszaros ZS, Abdul-Malak Y, Dimmock JA, et al. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial. J Clin Psychopharmacol. 2013;33:243–247.
  • Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA. 2014;311:145–154.
  • Kishi T, Iwata N. Varenicline for smoking cessation in people with schizophrenia: systematic review meta-analysis. Eur Arch Psychiatr. Clin Neurosci. 2015;265:259–268.
  • Hong LE, Thaker GK, McMahon RP, et al. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 2011;68:1195–1206.
  • Shim JC, Jung DU, Jung SS, et al. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology. 2012;37:660–668.
  • Evins AE, Mays VK, Rigotti NA, et al. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res. 2001;3:397–403.
  • George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry. 2002;52:53–61.
  • Fatemi SH, Stary JM, Hatsukami DK, et al. A double-blind placebo-controlled cross over trial of bupropion in smoking reduction in schizophrenia. Schizophr Res. 2005;76:353–356.
  • Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005a;25:218–225.
  • Evins AE, Deckersbach T, Cather C, et al. Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. J Clin Psychiatry. 2005b;66:1184–1190.
  • Weiner E, Ball MP, Buchholz AS, et al. Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis. J Clin Psychiatry. 2012;73:95–102.
  • Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007;27:380–386.
  • George TP, Vessicchio JC, Sacco KA, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry. 2008;63:1092–1096.
  • Kelly DL, McMahon RP, Weiner E, et al. Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia. Schizophr Res. 2008;103:161–168.
  • Weinberger AH, Sacco KA, Creeden CL, et al. Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia. Schizophr Res. 2007;91:217–225.

•• An up-to-date meta-analysis of RCTs involving varenicline for smoking cessation in schizophrenia with SUD.

  • Weinberger AH, George TP, Perkins KA, et al. Effects of topiramate on smoking in patients with schizoaffective disorders, bipolar type. J Clin Psychopharmacol. 2008;28:247–248.
  • Sacco KA, Creeden C, Rentenaner EL, et al. Effects of atomoxetine on cognitive functions and cigarette smoking in schizophrenia. Schizoph Res. 2009;107:332–333.
  • Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013;2:CD007253.

•• A meta-analysis of RCTs involving both pharmacological and psychosocial interventions for smoking cessation in schizophrenia with SUD.

  • Volkow ND, Fowler JS, Wang GJ, et al. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry. 2004;9:557–569.

•• A brilliant and evidence-based argumentation for the role of dopamine in drug use and which is paving the way for newer therapeutic strategies.

  • Andreasen NC, Pressler M, Nopoulos P, et al. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67:255–262.
  • Tsuang J, Marder SR, Han A, et al. Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychiatry. 2002;63:1180–1181.
  • Rüther T, Bobes J, De Hert M, et al. EPA Guidance on tobacco dependence and strategies for smoking cessation in people with mental illness. Eur Psychiatry. 2014;29:65–82.
  • Hasan A, Falkai P, Wobrock T, et al. Guidelines of Biological Treatment of Schizophrenia. Part 3. Update 2015. Management of special circumstances. Depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 2015;16:142–170.

•• An up-to-date guideline in the field with a gradation of recommendations for both psychotropic and anticraving agents when administered to schizophrenic patients with SUD.

  • Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692–699.
  • Becker MA, Young MS, Ochshorn E, et al. The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia. Adm Policy Ment Health. 2007;34:307–314.
  • Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatric Services. 2007;58:1187–1192.
  • Margolese HC, Malchy L, Negrete JC, et al. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res. 2004;67:157–166.
  • Owen RR, Fischer EP, Booth BM, et al. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatric Services. 1996;47:853–858.
  • Kreyenbuhl J, Slade EP, Medoff DR, et al. Time to discontinuation of first-and second-generation antipsychotic medications in the treatment of schizophrenia. Schizophr Res. 2011;131:127–132.
  • Smelson D, Tunis SL, Aw N, et al Substance use and antipsychotic treatment discontinuation in a 1 year randomized open label antipsychotic trial for schizophrenia. J Clin Psychopharmacol. 2006;26:666–667.
  • Agarval MR, Sharma VK, Kishore Kumar KV, et al. Non-compliance with treatment in patients suffering for schizophrenia: a study to evaluate possible contributing factors. Int J Soc Psychiatry. 1998;44:92–106.
  • Koola MM, Wehring HJ, Kelly DL. The potential role of long-acting injectable antipsychotics in people with schizophrenia and comorbid substance use. J Dual Diagn. 2012;8:50–61.

•• An excellent review which makes the case for the use of LAIs in schizophrenic patients with SUD.

  • Stip E, Abdel-Baki A, Bloom D, et al. Long-acting injectable antipsychotics: an expert opinion from the Association des médecins psychiatres du Québec. Can J Psychiatry. 2011;56:367–375.

•• A rational guideline for the use of LAI antipsychotics.

  • Adrian M, Barry SJ. Physical and mental health problems associated with use of alcohol and drugs. Subst Use Misuse. 2003;38:1575–1614.
  • Muniyappa R, Sable S, Ouwerkerk R, et al. Metabolic effects of chronic cannabis smoking. Diabetes Care. 2013;36:2415–2422.
  • Dickey B, Azeni H. Persons with dual diagnoses of substance abuse and major mental illness: their excess costs of psychiatric care. Am J of Public Health. 1996;86:973–977.
  • Gilman JM, Kuster JK, Lee S, et al. Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users. J Neurosci. 2014;34:5538–5529.
  • Scherck H, Falkai P. Effects of antipsychotics on brain structure. Curr Opin Psychiatry. 2006;19:145–150.
  • Smieskova R, Fusar-Poli P, Allen P, et al. The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia. A systematic review. Current Pharmaceutical Design. 2009;15:2535–2549.
  • Fusar-Poli P, Smieskova R, Kempton MJ, et al. Progressive brain changes in schizophrenia related to antipsychotic treatment ? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev. 2013;37:1680–1691.
  • Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol Med. 2009;39:1763–1777.
  • Moncrieff J, Leo J. A systematic review of the effects of antipsychotics drugs on brain volume. Psychol Med. 2010;40:1409–1422.
  • Gassó P, Mas S, Molina O, et al. Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36:71–77.
  • Gil-ad I, Shtaif B, Shiloh R, et al. Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms. Cell Mol Neurobiol. 2001;21:705–716.
  • Jarskog LF, Gilmore JH, Glantz LA, et al. Caspase-3 activation in rat frontal cortex following treatment with typical and atypical antipsychotics. Neuropsychopharmacology. 2007;32:95–102.
  • Qing H, Xu H, Wei Z, et al. The ability of atypical antipsychotic drugs vs haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur J Neurosc. 2003;17:1563–1570.
  • Skoblenick K, Castellano JM, Rogoza RM, et al. Translocation of AIF in the human and rat striatum following protracted haloperidol, but not clozapine treatment. Apoptosis. 2006;11:663–672.
  • Tan QR, Wang XZ, Wang CY, et al. Differential effects of classical and atypical antipsychotic drugs on rotenone-induced neurotoxicity in PC12 cells. Eur Neuropsychopharmacol. 2007;17:768–773.
  • Ukai W, Ozawa H, Tateno M, et al. Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. J Neural Transm. 2004;111:667–681.
  • Nasrallah H. Haloperidol clearly is neurotoxic. Should it be banned?. Curr Psychiatr. 2013;12:7–9.
  • Bartzokis G, Lu PH, Amar CP, et al. Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophr Res. 2011;132:35–41.
  • Bartzokis G, Lu PH, Raven EP, et al. Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophr Res. 2012;140:122–128.
  • Johnson MD, Heriza TJ, Dennis CS. How to spot illicit drug abuse in your patients. Postgrad Med. 1999;106:199–218.
  • Kosten TR, Kleber HD. Rapid death during cocaine abuse: Variant of the neuroleptic malignant syndrome?. Am J Drug Alcohol Abuse. 1988;14:335–346.
  • Dean A. Illicit drugs and drug interactions. Pharmacist. 2006;25:684–689.

•• A brief but straightforward review of potential pharmacodynamic and pharmacokinetic interactions with substances of abuse and drug treatment.

  • Soni SD, Brownlee M. Alcohol abuse in chronic schizophrenics: implications for management in the community. Acta Psychiatr Scand. 1991;84:272–276.
  • Farren CK, Hameedi FA, Rosen MA, et al. Significant interactions between clozapine and cocaine in cocaine addicts. Drug and Alcohol Dependence. 2000;59:153–163.
  • Tardy M, Huhn M, Kissling W, et al. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. Jul 2014;9(7):CD 009268. DOI:10.1002/14651858. CD009268. pub2. Review.
  • Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and summary statements. Schizoph Bull. 2010;36:71–93.

•• An outstanding review on the extrapyramidal, metabolic, and cardiovascular side effects of antipsychotics which provides comparative profiles of drugs for each of these effects.

  • Camm AJ, Karayal DN, Meltzer H, et al. Ziprasidone and the corrected QT interval. A comprehensive summary of clinical data. CNS Drugs. 2012;26:351–365.
  • Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of clinical trials. CNS Drug Rev. 2007;13:137–177.
  • Kelly DL, Gale EA, Conley RR, et al. Clozapine treatment in patients with prior substance abuse. Can J Psychiatry. 2003;48:111–114.
  • Wehring HJ, Thedford S, Koola M, et al. Patient and health care provider perspectives on long acting injectable antipsychotics in schizophrenia and the introduction of olanzapine long-acting injection. J Cent Nerv Syst Dis. 2011;3:107–123.
  • Varghese SP, Koola MM, Eiger R, et al. Opioid use remits, depression remains. Curr Psychiatr. 2014;13:45–50.
  • Bowen S, Chawla N, Collins SE, et al. Mindfulness-based prevention for substance use disorders: a pilot efficacy trial. Subst Abus. 2009;30:295–305.
  • Childress AR, O’Brien CP. Dopamine receptor partial agonists could address the duality of cocaine craving. Trends Pharmacol Sci. 2000;21:6–9.
  • Czoty PW, Nader MA. Effects of dopamine D2/D3 receptor ligands on food-cocaine choice in socially housed male cynomolgus monkeys. J Pharmacol Exp Ther. 2013;344:329–338.
  • Major LF, Lerner P, Ballenger JC, et al. Dopamine-beta-hydroxylase in the cerebrospinal fluid: relationship to disulfiram-induced psychosis. Biol Psychiatry. 1979;14:337–344.
  • Ventola CL. Off-label drug information. Regulation, distribution, evaluation, and related controversies. P&T. 2009;34:428–440.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.